Researchers showed KIT epitope editing let transplanted blood stem cells survive anti-KIT antibody conditioning, allowing hematopoietic stem/progenitor cell transplants as soon as 12 hours after treatment without chemo or radiation.
Two editing routes drove the effect: base editing installed KIT H378R and prime editing installed KIT D121L, while multiplex edits at BCL11A raised fetal hemoglobin to potentially treat sickle cell disease and β-thalassemia.
In mice, extended antibody dosing progressively enriched edited grafts—up to about 71% with Fab-79D regimens—while SR-1 selection of KIT D121L cells preserved multilineage engraftment and enabled near-complete replacement of prior grafts.
Patient-derived sickle-cell HSPCs exposed to antibody selection reached 83.6% KIT and 84.5% BCL11A editing with base editing, increasing HbF and lowering sickle hemoglobin above clinically relevant thresholds.
Safety analyses found no clonal dominance during in vivo selection, but flagged trade-offs: BCL11A base editing showed off-target deamination, and PE3 prime editing produced indels and low-frequency KIT-BCL11A translocations.
Is editing our genes to resist treatment a safer long-term bet than the known, harsh toxicities of chemotherapy?
This chemo-free gene therapy breakthrough is here, but how long until it can actually start saving patients' lives?
Non-Genotoxic KIT Epitope Editing Revolutionizes HSPC Transplantation: Expanding Access, Reducing Toxicity, and Shaping the Future of Curative Therapies
Overview
Hematopoietic stem/progenitor cell (HSPC) transplantation has long been a curative treatment for blood disorders, but its use has been limited by the need for highly toxic pre-transplant conditioning. Traditionally, patients must undergo intensive chemotherapy or radiation to deplete their own HSPCs, create space in the bone marrow for donor cells, and suppress the immune system to prevent rejection. While effective, these genotoxic regimens cause severe, sometimes life-threatening side effects, including organ damage and long-term complications. The report highlights a breakthrough non-genotoxic approach—KIT epitope editing—that promises safer, more precise conditioning, potentially expanding access to life-saving transplants for many more patients.